Mpox

Mpox is an exotic infectious disease caused by the Mpox virus. The disease was first identified in laboratory monkeys, thus earning its name, but in its natural state, it seems to infect rodents more than primates. A fever, headache, muscle pains, swollen lymph nodes, and fatigue are the first symptoms in humans. After this, a rash forms with blisters and crusts. Symptoms typically appear 7 to 14 days after exposure. In most cases, symptoms last 2 to 4 weeks. Children, pregnant women, and people with suppressed immune systems are at greater risk of severe cases.

Human Monkeypox – Epidemiology, Clinical Characteristics, Diagnosis, and Prevention

The human monkeypox virus, which belongs to the genus Orthopoxvirus of the family Poxviridae, is a DNA virus.

What is Monkeypox?

Monkeypox Epidemiology

Monkeypox 2003 U.S. Outbreak

Monkeypox; What is It and How Do We Treat It?

Latest Mpox News and Research

New class of antivirals shows promise against multiple viruses

The arrival of Paxlovid in December 2021 marked another turning point in the COVID-19 pandemic-;an effective antiviral that has since successfully treated millions.

11 Dec 2024

Interim analysis of STOMP study finds no efficacy for tecovirimat in mild to moderate Mpox cases

The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, according to an interim data analysis from the international clinical trial called the Study of Tecovirimat for Mpox (STOMP).

10 Dec 2024

Fossil fuel industry influences medical research, raising ethical concerns

An investigation published by The BMJ today reveals the extent of fossil fuel industry involvement in medical research, leading to fresh calls for academics and publishing companies to cut ties with companies.

28 Nov 2024

WHO grants Emergency Use Listing for LC16m8 mpox vaccine

The World Health Organization (WHO) has granted Emergency Use Listing (EUL) for the LC16m8 mpox vaccine, making it the second mpox vaccine to be supported by WHO following the Director-General's declaration of an mpox public health emergency of international concern (PHEIC) on 14 August 2024.

19 Nov 2024

New biosensor technology could revolutionize mpox diagnosis

A new variant of human mpox has claimed the lives of approximately 5% of people with reported infections in the Democratic Republic of the Congo since 2023, many of them children. Since then, it has spread to several other countries.

14 Nov 2024

As California taps pandemic stockpile for bird flu, officials keep close eye on spending

California public health officials are dipping into state and federal stockpiles to equip up to 10,000 farmworkers with masks, gloves, goggles, and other safety gear as the state confirms at least 21 human cases of bird flu as of early November.

14 Nov 2024

Mpox vaccine allocation targets 9 African countries

The Access and Allocation Mechanism (AAM) for mpox has allocated an initial 899 000 vaccine doses for 9 countries across the African region that are hit hard by the current mpox surge.

7 Nov 2024

WHO expands Emergency Use Listing for mpox diagnostics

As part of ongoing efforts to enhance quality-assured testing options, the World Health Organization (WHO) has listed two additional mpox in vitro diagnostics under its Emergency Use Listing (EUL) procedure.

30 Oct 2024

New initiative activated to strengthen response to mpox public health crisis

In October 2024, WHO and partners, in collaboration with Member States, activated the Global Health Emergency Corps (GHEC) for the first time to provide support to countries facing mpox outbreaks.

29 Oct 2024

African production of mpox vaccines could secure the continent’s health

As Africa grapples with multiple outbreaks of mpox, public health leaders say locally produced vaccines are vital to end donation dependence and secure the continent's health.

29 Oct 2024

Vaccination of young children could dramatically reduce mpox deaths in DRC

Vaccinating children under five-years-old in endemic mpox regions in the Democratic Republic of the Congo (DRC) would significantly reduce the number of deaths in the country, according to a new analysis by researchers at the Yale School of Public Health.

22 Oct 2024

New single-chain mRNA vaccines offer enhanced immunity and protection against mpox

Study reveals single-chain mRNA vaccines confer 100% protection against lethal mpox challenge in mice, marking a significant advancement in vaccine technology.

22 Oct 2024

New consortium launched to combat Mpox outbreak in Africa

University College Dublin (UCD) is leading MpoxVax AFRIVAC, a new €1.3 million international consortium that aims to rapidly deploy technology and develop new knowledge to end the current Mpox outbreak in the Democratic Republic of Congo (DRC) and surrounding countries.

17 Oct 2024

A review of clinical features, diagnosis, and management of Mpox

A comprehensive review in JAMA outlines monkeypox's clinical presentation and management, stressing the need for increased surveillance and vaccination efforts.

17 Oct 2024

Novel app enables surveillance of global travel-related illness

On around one in three trips someone falls ill, with gastrointestinal and respiratory complaints among the most common symptoms.

15 Oct 2024

FAU researchers highlight new vaccination barriers

Vaccines to prevent common and serious infectious diseases have had a greater impact on improving human health than any other medical advance of the 20th century, surpassing even sanitation and potable water. From the global eradication of smallpox in 1980 to the unprecedented development of effective and safe mRNA vaccines for COVID-19, vaccinations have played crucial roles in preventing millions of premature deaths and hospitalizations in adults and children.

8 Oct 2024

WHO lists first mpox in vitro diagnostic test under Emergency Use Listing

The World Health Organization (WHO) has listed the first mpox in vitro diagnostic (IVD) under its Emergency Use Listing (EUL) procedure, an important step in improving global access to mpox testing.

4 Oct 2024

New Health Impact Investment Platform launches to strengthen primary care

Execution is starting under the new Health Impact Investment Platform on the first country health investment plans turning original commitment into operational reality.

24 Sep 2024

Single dose of MVA-BN vaccine offers 58% protection against mpox

Researchers confirm the effectiveness of the modified vaccinia Ankara-Bavarian Nordic vaccine against mpox.

16 Sep 2024

NIH funds new research to combat emerging viruses

Albert Einstein College of Medicine has received a five-year, $14 million per year grant from the National Institute of Allergy and Infectious Diseases (NIAID) to participate in a broad national effort to develop "plug-and-play" vaccines and antibody-based therapies against a wide range of emerging viruses. The grant is part of NIAID's new Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network, which was announced earlier today.

14 Sep 2024